In accordance with the terms of 5 CFR 1320, this collection is approved for a period of eighteen months. The supporting statement notes that CVM intends to collect this information electronically "in the near future." Before resubmitting this collection to OMB, CVM should make arrangements to do so.
Inventory as of this Action
Requested
Previously Approved
05/31/2014
36 Months From Approved
11/30/2012
40
0
69
3
0
3
0
0
0
The Animal Generic Drug User Fee Act of 2008 (AGDUFA) (Title II of Public Law 110-316 signed by the President on August 14,2008), authorizes FDA to collect user fees for certain abbreviated applications for a generic new animal drug, on certain generic new animal drug products, and on certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs. A generic animal drug application submitted by a person subject to application fees is considered incomplete and will not be accepted for filing by FDA until all fees owed by such person has been paid.
AGDUFA requires the submission of the user fees concurrently with applications. If the required fees are not submitted, the review of the application will not begin. The "User Fee Cover Sheet" provides the information to either initiate or defer the application review.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.